Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: A report from an international DLBCL rituximab-CHOP consortium program study

Haematologica

Volumn 98, Issue 2, 2013, Pages 255-263

  Visco, Carlo ^a,b   Tzankov, Alexander ^c   Xu Monette, Zijun Y ^a   Miranda, Roberto N ^a   Tai, Yu Chuan ^d   Li, Yan ^d   Liu, Wei Min ^d   d'Amore, Emanuele S G ^b   Li, Yong ^e   Montes Moreno, Santiago ^f   Dybkær, Karen ^g   Chiu, April ^h   Orazi, Attilio ⁱ   Zu, Youli ^j   Bhagat, Govind ^k   Wang, Huan You ^l   Dunphy, Cherie H ^m   His, Eric D ⁿ   Zhao, X Frank ^o   Choi, William W L ^p   Zhao, Xiaoying ^q   Han van Krieken, J ^r   Huang, Qin ^s   Ai, Weiyun ^t   O'Neill, Stacey ^m   Ponzoni, Maurilio ^u   Ferreri, Andres J M ^u   Kahl, Brad S ^v   Winter, Jane N ^w   Go, Ronald S ^x   Dirnhofer, Stephan ^c   Piris, Miguel A ^f   Møller, Michael B ^y   Wu, Lin ^d   Medeiros, L Jeffrey ^a   Young, Ken H ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SAN BORTOLO HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d ROCHE MOLECULAR SYSTEMS   (United States)

^e University of Louisville School of Medicine   (United States)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j HOUSTON METHODIST HOSPITAL   (United States)

^k NewYork Presbyterian Hospital   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁿ LERNER RESEARCH INSTITUTE   (United States)

^o UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF HONG KONG   (Hong Kong)

^q THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^r RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^s CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u SAN RAFFAELE HOSPITAL   (Italy)

^v University of Wisconsin Health   (United States)

^w NORTHWESTERN UNIVERSITY   (United States)

^x GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^y ODENSE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; CYCLOPHOSPHAMIDE; DOXORUBICIN; MYC PROTEIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN BCL 2; R-CHOP PROTOCOL;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHROMOSOME REARRANGEMENT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE MYC; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; VALIDATION PROCESS; ADOLESCENT; CHROMOSOME 14; CHROMOSOME 18; GENE TRANSLOCATION; GENETICS; GERMINAL CENTER; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; GENES, MYC; GERMINAL CENTER; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSLOCATION, GENETIC; VINCRISTINE; YOUNG ADULT;

EID: 84875314276     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.066209     Document Type: Article

References (41)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. WHO Classification of Tumours of Haematopoietic and Lymphoid tissues. Lyon, France, IARC press. 2008.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11.
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25): 1937-47.
4. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expressionbased method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100(17):9991-6.
5. Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center Bcell- like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(28):4587-94.
6. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 1987;317(19):1185-9.
7. Hill ME, MacLennan KA, Cunningham DC, Vaughan HB, Burke M, Clarke P, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood. 1996;88(3):1046-51.
8. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99(7):2285-90.
9. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228(4706): 1440-3.
10. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165(1):159-66.
11. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90(1):244-51.
12. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92(9):3152-62.
13. Martinka M, Comeau T, Foyle A, Anderson D, Greer W. Prognostic significance of t(14;18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma. Clin Invest Med. 1997;20(6):364-70.
14. Vitolo U, Gaidano G, Botto B, Volpe G, Audisio E, Bertini M, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in Bdiffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol. 1998;9(1):55-61.
15. Offit K, Koduru PR, Hollis R, Filippa D, Jhanwar SC, Clarkson BC, et al. 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. Br J Haematol. 1989;72(2):178-83.
16. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med. 1989;320(16):1047-54.
17. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S. Clinical significance of bcl-2- MBR gene rearrangement and protein expression in diffuse large-cell non- Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol. 1994;12(1):149-54.
18. Barrans SL, Evans PA, O'Connor SJ, Kendall SJ, Owen RG, Haynes AP, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res. 2003;9(6):2133-9.
19. Bea S, Colomo L, Lopez-Guillermo A, Salaverria I, Puig X, Pinyol M, et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol. 2004;22(17):3498-506.
20. Obermann EC, Csato M, Dirnhofer S, Tzankov A. BCL2 gene aberration as an IPIindependent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma. J Clin Pathol. 2009;62(10):903-7.
21. Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol. 2009;27(33):5573-9.
22. Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOPlike therapy and rituximab. Clin Cancer Res. 2011;17(24):7785-95.
23. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-5.
24. Johnson NA, Savage KJ, Ludkovski O, Ben- Neriah S, Woods R, Steidl C, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11): 2273-9.
25. Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2012;118(17):4173-83.
26. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861-74.
27. Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2009;100(10):1842-7.
28. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-- associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101(11):4279-84.
29. Wilson KS, Sehn LH, Berry B, Chhanabhai M, Fitzgerald CA, Gill KK, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma. 2007;48(6):1102-9.
30. Shivakumar L, Armitage JO. Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma. 2006;6(6):455-7.
31. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-5.
32. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26(9):2103-13.
33. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86.
34. Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. Blood. 2012;119(8): 1882-7.
35. Mao P, Hever MP, Niemaszyk LM, Haghkerdar JM, Yanco EG, Desai D, et al. Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells. J Biol Chem. 2011;286(22): 19381-91.
36. Bodemann BO, White MA. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer. 2008;8(2):133-40.
37. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997; 277(5328):965-8.
38. Chen Y, Han T, Iqbal J, Irons R, Chan WC, Zhu X, et al. Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. Am J Clin Pathol. 2010;133(2):305-13.
39. Nyman H, Jerkeman M, Karjalainen- Lindsberg ML, Banham AH, Enblad G, Leppa S. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur J Haematol. 2009;82(5):364-72.
40. Song MK, Chung JS, Shin DH, Seol YM, Shin HJ, Choi YJ, et al. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP. Leuk Lymphoma. 2009;50(1):54-61.
41. Satterwhite E, Sonoki T, Willis TG, Harder L, Nowak R, Arriola EL, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood. 2001;98 (12):3413-20.